{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:37:20Z","timestamp":1791970640973,"version":"4.3.4"},"reference-count":128,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015340","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019944","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016304","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Atrial fibrillation (AF) is one of the most common cardiac diseases and a complicating comorbidity for multiple associated diseases. Many clinical decisions regarding AF are currently based on the binary recognition of AF being present or absent with the categorical appraisal of AF as continued or intermittent. Assessment of AF in clinical trials is largely limited to the time to (first) detection of an AF episode. Substantial evidence shows, however, that the quantitative characteristic of intermittent AF has a relevant impact on symptoms, onset, and progression of AF and AF-related outcomes, including mortality. Atrial fibrillation burden is increasingly recognized as a suitable quantitative measure of intermittent AF that provides an estimate of risk attributable to AF, the efficacy of antiarrhythmic treatment, and the need for oral anticoagulation. However, the diversity of assessment methods and the lack of a consistent definition of AF burden prevent a wider clinical applicability and validation of actionable thresholds of AF burden. To facilitate progress in this field, the AF burden Consensus Group, an international and multidisciplinary collaboration, proposes a unified definition of AF burden. Based on current evidence and using a modified Delphi technique, consensus statements were attained on the four main areas describing AF burden: Defining the characteristics of AF burden, the recording principles, the clinical relevance in major clinical conditions, and implementation as an outcome in the clinic and in clinical trials. According to this consensus, AF burden is defined as the proportion of time spent in AF expressed as a percentage of the recording time, undertaken during a specified monitoring duration. A pivotal requirement for validity and comparability of AF burden assessment is a continuous or near-continuous duration of monitoring that needs to be reported together with the AF burden assessment. This proposed unified definition of AF burden applies independent of comorbidities and outcomes. However, the disease-specific actionable thresholds of AF burden need to be defined according to the targeted clinical outcomes in specific populations. The duration of the longest episode of uninterrupted AF expressed as a time duration should also be reported when appropriate. A unified definition of AF burden will allow for comparability of clinical study data to expand evidence and to establish actionable thresholds of AF burden in various clinical conditions. This proposed definition of AF burden will support risk evaluation and clinical treatment decisions in AF-related disease. It will further promote the development of clinical trials studying the clinical relevance of intermittent AF. A unified approach on AF burden will finally inform the technology development of heart rhythm monitoring towards validated technology to meet clinical needs.<\/jats:p>","DOI":"10.1093\/europace\/euaf019","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T13:56:11Z","timestamp":1741787771000},"source":"Crossref","is-referenced-by-count":139,"title":["Atrial fibrillation burden in clinical practice, research, and technology development: a clinical consensus statement of the European Society of Cardiology Council on Stroke and the European Heart Rhythm Association"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7598-708X","authenticated-orcid":false,"given":"Wolfram","family":"Doehner","sequence":"first","affiliation":[{"name":"Berlin Institute of Health Center for Regenerative Therapies, Charit\u00e9 -Universit\u00e4tsmedizin Berlin , F\u00f6hrerstr. 15, Berlin 13353 ,","place":["Germany"]},{"name":"Deutsches Herzzentrum der Charit\u00e9, Department of Cardiology Angiology and Intensive Care Medicine (Campus Virchow), Charit\u00e9 - Universit\u00e4tsmedizin Berlin, German Centre for Cardiovascular Research (DZHK) partner site Berlin, Augustenburger Platz 1, Berlin 13353, Germany"},{"name":"Center for Stroke Research Berlin, Charit\u00e9 - Universit\u00e4tsmedizin Berlin , Charit\u00e9platz 1, Berlin 10117 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9820-4815","authenticated-orcid":false,"given":"Giuseppe","family":"Boriani","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena , Modena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6285-6902","authenticated-orcid":false,"given":"Tatjana","family":"Potpara","sequence":"additional","affiliation":[{"name":"Medical Faculty, University of Belgrade , Dr Subotica 13, 11000 Belgrade ,","place":["Serbia"]},{"name":"Cardiology Clinic, University Clinical Centre of Serbia , Belgrade ,","place":["Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2806-3903","authenticated-orcid":false,"given":"Carina","family":"Blomstrom-Lundqvist","sequence":"additional","affiliation":[{"name":"Department of Cardiology, School of Medical Sciences, Faculty of Medicine and Health, \u00d6rebro University , \u00d6rebro ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8718-1534","authenticated-orcid":false,"given":"Rod","family":"Passman","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6425-9343","authenticated-orcid":false,"given":"Luciano A","family":"Sposato","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurological Sciences and Brain & Heart Lab, Western University , London, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4612-117X","authenticated-orcid":false,"given":"Dobromir","family":"Dobrev","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg\u2014Essen , Essen ,","place":["Germany"]},{"name":"Montr\u00e9al Heart Institute, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, Qu\u00e9bec ,","place":["Canada"]},{"name":"Department of Integrative Physiology, Baylor College of Medicine , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3809-2911","authenticated-orcid":false,"given":"Ben","family":"Freedman","sequence":"additional","affiliation":[{"name":"Heart Research Institute, Sydney Medical School, Charles Perkins Centre, and Department of Cardiology, Concord Hospital, The University of Sydney , Sydney ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7579-1201","authenticated-orcid":false,"given":"Isabelle C","family":"Van Gelder","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5286-2612","authenticated-orcid":false,"given":"Taya V","family":"Glotzer","sequence":"additional","affiliation":[{"name":"Division of Cardiac Electrophysiology, Hackensack University Medical Center , Hackensack, NJ 07601 ,","place":["USA"]},{"name":"Hackensack Meridian School of Medicine , Hackensack, NJ 07601 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1216-7580","authenticated-orcid":false,"given":"Jeff S","family":"Healey","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University , Hamilton, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2357-7967","authenticated-orcid":false,"given":"Theodore","family":"Karapanayiotides","sequence":"additional","affiliation":[{"name":"2nd Department of Neurology, Aristotle University of Thessaloniki, School of Medicine, AHEPA University Hospital , Thessaloniki ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital , Liverpool ,","place":["UK"]},{"name":"Department of Clinical Medicine, Aalborg University , Aalborg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1737-1903","authenticated-orcid":false,"given":"Jose Luis","family":"Merino","sequence":"additional","affiliation":[{"name":"Arrhythmia and Robotic Electrophysiology Unit, La Paz University Hospital-IdiPaz, Autonoma University , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0629-9248","authenticated-orcid":false,"given":"George","family":"Ntaios","sequence":"additional","affiliation":[{"name":"1st Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, AHEPA University Hospital , Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7170-9509","authenticated-orcid":false,"given":"Renate B","family":"Schnabel","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg\u2014Eppendorf , Hamburg ,","place":["Germany"]},{"name":"German Center for Cardiovascular Research (DZHK) partner site Hamburg\/Kiel\/L\u00fcbeck , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8466-8515","authenticated-orcid":false,"given":"Jesper H","family":"Svendsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital\u2014Rigshospitalet , Copenhagen ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Medical Sciences, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6413-0870","authenticated-orcid":false,"given":"Emma","family":"Svennberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet, Karolinska University Hospital , Huddinge, Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2231-2200","authenticated-orcid":false,"given":"Rolf","family":"Wachter","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Leipzig , Leipzig ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6389-5054","authenticated-orcid":false,"given":"Karl Georg","family":"Haeusler","sequence":"additional","affiliation":[{"name":"Department of Neurology, Universit\u00e4tsklinikum Ulm , Ulm ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2536-2871","authenticated-orcid":false,"given":"A John","family":"Camm","sequence":"additional","affiliation":[{"name":"Clinical Cardiac Academic Group, Genetic and Cardiovascular Sciences Institute, City-St George\u2019s University of London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"2026080913422452300_euaf019-B1","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2026080913422452300_euaf019-B2","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1016\/j.jacc.2014.04.019","article-title":"Clinical classifications of atrial fibrillation poorly reflect its temporal persistence: insights from 1,195 patients continuously monitored with implantable devices","volume":"63","author":"Charitos","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080913422452300_euaf019-B3","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.119.041303","article-title":"Stroke risk as a function of atrial fibrillation duration and CHA(2)DS(2)-VASc score","volume":"140","author":"Kaplan","year":"2019","journal-title":"Circulation"},{"key":"2026080913422452300_euaf019-B4","doi-asserted-by":"crossref","first-page":"e010304","DOI":"10.1161\/CIRCEP.121.010304","article-title":"Arrhythmic burden and the risk of cardiovascular outcomes in patients with paroxysmal atrial fibrillation and cardiac implanted electronic devices","volume":"15","author":"Chew","year":"2022","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2026080913422452300_euaf019-B5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/europace\/eum268","article-title":"Impact of anti-tachycardia pacing on atrial fibrillation burden when added on top of preventive pacing algorithms: results of the prevention or termination (POT) trial","volume":"10","author":"Mont","year":"2008","journal-title":"Europace"},{"key":"2026080913422452300_euaf019-B6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/europace\/eun294","article-title":"Reduction of atrial fibrillation burden by atrial overdrive pacing: experience with an improved algorithm to reduce early recurrences of atrial fibrillation","volume":"11","author":"Purerfellner","year":"2009","journal-title":"Europace"},{"key":"2026080913422452300_euaf019-B7","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/europace\/eup115","article-title":"Impact of atrial antitachycardia pacing and atrial pace prevention therapies on atrial fibrillation burden over long-term follow-up","volume":"11","author":"Gillis","year":"2009","journal-title":"Europace"},{"key":"2026080913422452300_euaf019-B8","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/europace\/euq463","article-title":"The relationship between right ventricular pacing and atrial fibrillation burden and disease progression in patients with paroxysmal atrial fibrillation: the long-MinVPACE study","volume":"13","author":"Veasey","year":"2011","journal-title":"Europace"},{"key":"2026080913422452300_euaf019-B9","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.amjcard.2013.04.049","article-title":"Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients","volume":"112","author":"Deftereos","year":"2013","journal-title":"Am J Cardiol"},{"key":"2026080913422452300_euaf019-B10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10840-014-9966-z","article-title":"A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers","volume":"42","author":"Ezekowitz","year":"2015","journal-title":"J Interv Card Electrophysiol"},{"key":"2026080913422452300_euaf019-B11","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/europace\/euv263","article-title":"First clinical trial of specific IKACh blocker shows no reduction in atrial fibrillation burden in patients with paroxysmal atrial fibrillation: pacemaker assessment of BMS 914392 in patients with paroxysmal atrial fibrillation","volume":"18","author":"Podd","year":"2016","journal-title":"Europace"},{"key":"2026080913422452300_euaf019-B12","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.hrthm.2018.06.027","article-title":"Intermittent anticoagulation guided by continuous atrial fibrillation burden monitoring using dual-chamber pacemakers and implantable cardioverter-defibrillators: results from the tailored anticoagulation for non-continuous atrial fibrillation (TACTIC-AF) pilot study","volume":"15","author":"Waks","year":"2018","journal-title":"Heart Rhythm"},{"key":"2026080913422452300_euaf019-B13","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2029980","article-title":"Cryoablation or drug therapy for initial treatment of atrial fibrillation","volume":"384","author":"Andrade","year":"2021","journal-title":"N Engl J Med"},{"key":"2026080913422452300_euaf019-B14","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.amjcard.2017.07.018","article-title":"Natriuretic propeptides as markers of atrial fibrillation burden and recurrence (from the AMIO-CAT trial)","volume":"120","author":"Darkner","year":"2017","journal-title":"Am J Cardiol"},{"key":"2026080913422452300_euaf019-B15","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacep.2020.11.021","article-title":"Atrial fibrillation burden and clinical outcomes in heart failure: the CASTLE-AF trial","volume":"7","author":"Brachmann","year":"2021","journal-title":"JACC Clin Electrophysiol"},{"key":"2026080913422452300_euaf019-B16","doi-asserted-by":"crossref","first-page":"e623","DOI":"10.1161\/CIR.0000000000000568","article-title":"Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the American Heart Association","volume":"137","author":"Chen","year":"2018","journal-title":"Circulation"},{"key":"2026080913422452300_euaf019-B17","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/europace\/euaa287","article-title":"Atrial fibrillation burden: an update-the need for a CHA2DS2-VASc-AFBurden score","volume":"23","author":"Tiver","year":"2021","journal-title":"Europace"},{"key":"2026080913422452300_euaf019-B18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080913422452300_euaf019-B19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026080913422452300_euaf019-B20","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1093\/eurheartj\/ehae373","article-title":"Atrial fibrillation burden: a new outcome predictor and therapeutic target","volume":"45","author":"Becher","year":"2024","journal-title":"Eur Heart J"},{"key":"2026080913422452300_euaf019-B21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","article-title":"Delphi methodology in healthcare research: how to decide its appropriateness","volume":"11","author":"Nasa","year":"2021","journal-title":"World J Methodol"},{"key":"2026080913422452300_euaf019-B22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/eurheartj\/ehu307","article-title":"Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES","volume":"36","author":"Vanassche","year":"2015","journal-title":"Eur Heart J"},{"key":"2026080913422452300_euaf019-B23","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1161\/CIRCULATIONAHA.112.098079","article-title":"A comprehensive evaluation of rhythm monitoring strategies for the detection of atrial fibrillation recurrence: insights from 647 continuously monitored patients and implications for monitoring after therapeutic interventions","volume":"126","author":"Charitos","year":"2012","journal-title":"Circulation"},{"key":"2026080913422452300_euaf019-B24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.hrthm.2018.08.012","article-title":"Identification of paroxysmal atrial fibrillation subtypes in over 13,000 individuals","volume":"16","author":"Wineinger","year":"2019","journal-title":"Heart Rhythm"},{"key":"2026080913422452300_euaf019-B25","first-page":"6","article-title":"Improved end point for atrial fibrillation therapies: a modified atrial fibrillation burden score to account for both rhythm and rate control","volume":"23","author":"Knight","year":"2023","journal-title":"EP Lab Dig"},{"key":"2026080913422452300_euaf019-B26","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/jce.16108","article-title":"Does asymptomatic atrial fibrillation exist?","volume":"35","author":"Carneiro","year":"2024","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026080913422452300_euaf019-B27","doi-asserted-by":"crossref","first-page":"ii29","DOI":"10.1093\/europace\/euab318","article-title":"Reflections on the usefulness of today's atrial fibrillation ablation procedure endpoints and patient-reported outcomes","volume":"24","author":"Blomstr\u00f6m-Lundqvist","year":"2022","journal-title":"Europace"},{"key":"2026080913422452300_euaf019-B28","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/jocn.13951","article-title":"Management of newly diagnosed atrial fibrillation in an outpatient clinic setting-patient's perspectives and experiences","volume":"27","author":"Thrysoee","year":"2018","journal-title":"J Clin Nurs"},{"key":"2026080913422452300_euaf019-B29","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.jacc.2020.01.046","article-title":"Wearable devices for ambulatory cardiac monitoring: JACC state-of-the-art review","volume":"75","author":"Sana","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026080913422452300_euaf019-B30","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/pace.12389","article-title":"Atrial fibrillation burden estimates derived from intermittent rhythm monitoring are unreliable estimates of the true atrial fibrillation burden","volume":"37","author":"Charitos","year":"2014","journal-title":"Pacing Clin Electrophysiol"},{"key":"2026080913422452300_euaf019-B31","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.2019.0335","article-title":"Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation\u2014the CAPTAF randomized clinical trial","volume":"321","author":"Blomstr\u00f6m-Lundqvist","year":"2019","journal-title":"JAMA"},{"key":"2026080913422452300_euaf019-B32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.121.056109","article-title":"Influence of monitoring strategy on assessment of ablation success and postablation atrial fibrillation burden assessment: implications for practice and clinical trial design","volume":"145","author":"Aguilar","year":"2022","journal-title":"Circulation"},{"key":"2026080913422452300_euaf019-B33","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/jce.13745","article-title":"Outcomes of paroxysmal atrial fibrillation ablation studies are affected more by study design and patient mix than ablation technique","volume":"29","author":"Ferreira-Martins","year":"2018","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026080913422452300_euaf019-B34","doi-asserted-by":"crossref","first-page":"f312","DOI":"10.1093\/europace\/euy038","article-title":"Continuous monitoring after atrial fibrillation ablation: the LINQ AF study","volume":"20","author":"Wechselberger","year":"2018","journal-title":"Europace"},{"key":"2026080913422452300_euaf019-B35","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1161\/CIRCULATIONAHA.119.044407","article-title":"Comprehensive evaluation of rhythm monitoring strategies in screening for atrial fibrillation: insights from patients at risk monitored long term with an implantable loop recorder","volume":"141","author":"Diederichsen","year":"2020","journal-title":"Circulation"},{"key":"2026080913422452300_euaf019-B36","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.amjcard.2015.06.012","article-title":"A comparison of atrial fibrillation monitoring strategies after cryptogenic stroke (from the cryptogenic stroke and underlying AF trial)","volume":"116","author":"Choe","year":"2015","journal-title":"Am J Cardiol"},{"key":"2026080913422452300_euaf019-B37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/CIRCEP.109.877852","article-title":"XPECT trial investigators. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation: results of the XPECT trial","volume":"3","author":"Hindricks","year":"2010","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2026080913422452300_euaf019-B38","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jacep.2020.12.006","article-title":"AI filter improves positive predictive value of atrial fibrillation detection by an implantable loop recorder","volume":"7","author":"Mittal","year":"2021","journal-title":"JACC Clin Electrophysiol"},{"key":"2026080913422452300_euaf019-B39","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jacep.2023.12.011","article-title":"Impact of atrial fibrillation burden on health care costs and utilization","volume":"10","author":"Peigh","year":"2024","journal-title":"JACC Clin Electrophysiol"},{"key":"2026080913422452300_euaf019-B40","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00392-021-01941-9","article-title":"Mobile health solutions for atrial fibrillation detection and management: a systematic review","volume":"111","author":"Hermans","year":"2022","journal-title":"Clin Res Cardiol"},{"key":"2026080913422452300_euaf019-B41","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1007\/s40615-022-01446-9","article-title":"Accuracy of heart rate measurement with wrist-worn wearable devices in various skin tones: a systematic review","volume":"10","author":"Koerber","year":"2023","journal-title":"J Racial Ethn Health Disparities"},{"key":"2026080913422452300_euaf019-B42","doi-asserted-by":"crossref","first-page":"e0148914","DOI":"10.1371\/journal.pone.0148914","article-title":"Simulation of daily snapshot rhythm monitoring to identify atrial fibrillation in continuously monitored patients with stroke risk factors","volume":"11","author":"Yano","year":"2016","journal-title":"PLoS One"},{"key":"2026080913422452300_euaf019-B43","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1901183","article-title":"Apple heart study investigators. Large-scale assessment of a smartwatch to identify atrial fibrillation","volume":"381","author":"Perez","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080913422452300_euaf019-B44","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1161\/CIRCULATIONAHA.122.060291","article-title":"Detection of atrial fibrillation in a large population using wearable devices: the fitbit heart study","volume":"146","author":"Lubitz","year":"2022","journal-title":"Circulation"},{"key":"2026080913422452300_euaf019-B45"},{"key":"2026080913422452300_euaf019-B46","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jacc.2011.03.034","article-title":"Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation RECORDAF (registry on cardiac rhythm disorders assessing the control of atrial fibrillation)","volume":"58","author":"Camm","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026080913422452300_euaf019-B47","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.ijcard.2012.04.131","article-title":"The type of atrial fibrillation is associated with long-term outcome in patients with acute ischemic stroke","volume":"167","author":"Ntaios","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026080913422452300_euaf019-B48","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/eurheartj\/ehx042","article-title":"Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT","volume":"38","author":"Van Gelder","year":"2017","journal-title":"Eur Heart J"},{"key":"2026080913422452300_euaf019-B49","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/eurheartj\/eht491","article-title":"Device-detected atrial fibrillation and risk for stroke: an analysis of &gt;10,000 patients from the SOS AF project (stroke prevention strategies based on atrial fibrillation information from implanted devices)","volume":"35","author":"Boriani","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080913422452300_euaf019-B50","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/eurheartj\/ehad771","article-title":"Anticoagulation with edoxaban in patients with long atrial high-rate episodes \u226524 h","volume":"45","author":"Becher","year":"2024","journal-title":"Eur Heart J"},{"key":"2026080913422452300_euaf019-B51","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1001\/jamacardio.2021.3702","article-title":"Temporal association between episodes of atrial fibrillation and risk of ischemic stroke","volume":"6","author":"Singer","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026080913422452300_euaf019-B52","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1105575","article-title":"Subclinical atrial fibrillation and the risk of stroke","volume":"366","author":"Healey","year":"2012","journal-title":"N Engl J Med"},{"key":"2026080913422452300_euaf019-B53","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/jamacardio.2018.1176","article-title":"Association of burden of atrial fibrillation with risk of ischemic stroke in adults with paroxysmal atrial fibrillation: the KP-RHYTHM study","volume":"3","author":"Go","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026080913422452300_euaf019-B54","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1056\/NEJMoa2303062","article-title":"Anticoagulation with edoxaban in patients with atrial high-rate episodes","volume":"389","author":"Kirchhof","year":"2023","journal-title":"N Engl J Med"},{"key":"2026080913422452300_euaf019-B55","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa2310234","article-title":"Apixaban for stroke prevention in subclinical atrial fibrillation","volume":"390","author":"Healey","year":"2024","journal-title":"N Engl J Med"},{"key":"2026080913422452300_euaf019-B56","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jacc.2024.05.002","article-title":"Apixaban vs aspirin according to CHA2DS2-VASc score in subclinical atrial fibrillation: insights from ARTESiA","volume":"84","author":"Lopes","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026080913422452300_euaf019-B57","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1161\/CIRCULATIONAHA.123.067512","article-title":"Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials","volume":"149","author":"McIntyre","year":"2024","journal-title":"Circulation"},{"key":"2026080913422452300_euaf019-B58","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1161\/CIRCULATIONAHA.124.069903","article-title":"Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: insights from the ARTESiA trial","volume":"150","author":"McIntyre","year":"2024","journal-title":"Circulation"},{"key":"2026080913422452300_euaf019-B59","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WCO.0000000000000410","article-title":"The complexity of atrial fibrillation newly diagnosed after ischemic stroke and TIA: advances and uncertainties","volume":"30","author":"Cerasuolo","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"2026080913422452300_euaf019-B60","doi-asserted-by":"crossref","first-page":"e924","DOI":"10.1212\/WNL.0000000000005126","article-title":"Atrial fibrillation detected after stroke is related to a low risk of ischemic stroke recurrence","volume":"90","author":"Sposato","year":"2018","journal-title":"Neurology"},{"key":"2026080913422452300_euaf019-B61","doi-asserted-by":"crossref","first-page":"e1942","DOI":"10.1212\/WNL.0000000000200227","article-title":"Prolonged cardiac monitoring and stroke recurrence: a meta-analysis","volume":"98","author":"Tsivgoulis","year":"2022","journal-title":"Neurology"},{"key":"2026080913422452300_euaf019-B62","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000520101","article-title":"Clinical and prognostic differences between atrial fibrillation detected before and after stroke and TIA","volume":"51","author":"Fridman","year":"2022","journal-title":"Cerebrovasc Dis"},{"key":"2026080913422452300_euaf019-B63","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.03.019","article-title":"High incidence of occult atrial fibrillation in Asian patients with cryptogenic stroke","volume":"27","author":"Seow","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2026080913422452300_euaf019-B64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10840-021-00985-1","article-title":"Predictors of atrial fibrillation on implantable cardiac monitoring for cryptogenic stroke","volume":"65","author":"Desai","year":"2022","journal-title":"J Interv Card Electrophysiol"},{"key":"2026080913422452300_euaf019-B65","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/STROKEAHA.123.043672","article-title":"Differences in stroke recurrence risk between atrial fibrillation detected on ECG and 14-day cardiac monitoring","volume":"54","author":"Alvarado-Bola\u00f1os","year":"2023","journal-title":"Stroke"},{"key":"2026080913422452300_euaf019-B66","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1161\/CIRCEP.109.849638","article-title":"The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study","volume":"2","author":"Glotzer","year":"2009","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2026080913422452300_euaf019-B67","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1474-4422(17)30002-9","article-title":"Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (find-AF(RANDOMISED)): an open-label randomised controlled trial","volume":"16","author":"Wachter","year":"2017","journal-title":"Lancet Neurol"},{"key":"2026080913422452300_euaf019-B68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cvr\/cvab147","article-title":"Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes","volume":"117","author":"Boriani","year":"2021","journal-title":"Cardiovasc Res"},{"key":"2026080913422452300_euaf019-B69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/ejhf.2729","article-title":"Intersection of atrial fibrillation and heart failure with mildly reduced and preserved ejection fraction in &gt;400,000 participants in the get with the guidelines heart failure registry","volume":"25","author":"Patel","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080913422452300_euaf019-B70","doi-asserted-by":"crossref","first-page":"euad095","DOI":"10.1093\/europace\/euad095","article-title":"Atrial fibrillation can adversely impact heart failure with preserved ejection fraction by its association with heart failure progression and mortality: a post-hoc propensity score-matched analysis of the TOPCAT Americas trial","volume":"25","author":"Saksena","year":"2023","journal-title":"Europace"},{"key":"2026080913422452300_euaf019-B71","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejim.2023.09.009","article-title":"Asymptomatic vs. symptomatic atrial fibrillation: clinical outcomes in heart failure patients","volume":"119","author":"Boriani","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2026080913422452300_euaf019-B72","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jchf.2019.03.005","article-title":"Heart failure and atrial fibrillation, like fire and fury","volume":"7","author":"Carlisle","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026080913422452300_euaf019-B73","doi-asserted-by":"crossref","first-page":"11","DOI":"10.31083\/j.rcm.2021.01.134","article-title":"Imaging in heart failure with preserved ejection fraction: insights into echocardiography and cardiac magnetic resonance imaging","volume":"22","author":"Chacon-Portillo","year":"2021","journal-title":"Rev Cardiovasc Med"},{"key":"2026080913422452300_euaf019-B74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2022.01.019","article-title":"Heart failure with preserved ejection fraction: squaring the circle between comorbidities and cardiovascular abnormalities","volume":"99","author":"Marra","year":"2022","journal-title":"Eur J Intern Med"},{"key":"2026080913422452300_euaf019-B75","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.hrthm.2021.01.021","article-title":"Atrial fibrillation burden and heart failure: data from 39,710 individuals with cardiac implanted electronic devices","volume":"18","author":"Steinberg","year":"2021","journal-title":"Heart Rhythm"},{"key":"2026080913422452300_euaf019-B76","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.hroo.2021.09.015","article-title":"Heart failure with preserved ejection fraction: an alternative paradigm to explain the clinical implications of atrial fibrillation","volume":"2","author":"Ariyaratnam","year":"2021","journal-title":"Heart Rhythm O2"},{"key":"2026080913422452300_euaf019-B77","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/europace\/eux301","article-title":"Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational research programme on atrial fibrillation (EORP-AF) long-term general registry","volume":"20","author":"Boriani","year":"2018","journal-title":"Europace"},{"key":"2026080913422452300_euaf019-B78","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jacc.2020.07.009","article-title":"Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation","volume":"76","author":"Reddy","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026080913422452300_euaf019-B79","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure","volume":"378","author":"Marrouche","year":"2018","journal-title":"N Engl J Med"},{"key":"2026080913422452300_euaf019-B80","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJMoa2306037","article-title":"Catheter ablation in end-stage heart failure with atrial fibrillation","volume":"389","author":"Sohns","year":"2023","journal-title":"N Engl J Med"},{"key":"2026080913422452300_euaf019-B81","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/heartjnl-2022-321027","article-title":"Prevalence and determinants of atrial fibrillation progression in paroxysmal atrial fibrillation","volume":"109","author":"Nguyen","year":"2022","journal-title":"Heart"},{"key":"2026080913422452300_euaf019-B82","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1016\/j.jacc.2018.03.519","article-title":"Progression of device-detected subclinical atrial fibrillation and the risk of heart failure","volume":"71","author":"Wong","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026080913422452300_euaf019-B83","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/europace\/euy222","article-title":"Atrial fibrillation burden, progression, and the risk of death: a case-crossover analysis in patients with cardiac implantable electronic devices","volume":"21","author":"Piccini","year":"2019","journal-title":"Europace"},{"key":"2026080913422452300_euaf019-B84","first-page":"741","article-title":"Data mining experiments on the angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF-AFNET 2) trial: \u2018exposing the invisible\u2019","volume":"19","author":"Okutucu","year":"2017","journal-title":"Europace"},{"key":"2026080913422452300_euaf019-B85","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrneph.2018.19","article-title":"Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction","volume":"14","author":"Potpara","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"2026080913422452300_euaf019-B86","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2215\/CJN.10921015","article-title":"Atrial fibrillation and risk of ESRD in adults with CKD","volume":"11","author":"Bansal","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026080913422452300_euaf019-B87","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jjcc.2020.07.002","article-title":"Improvement in renal and endothelial function after catheter ablation in patients with persistent atrial fibrillation","volume":"76","author":"Okawa","year":"2020","journal-title":"J Cardiol"},{"key":"2026080913422452300_euaf019-B88","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/europace\/eux031","article-title":"Does atrial fibrillation cause cognitive decline and dementia?","volume":"20","author":"Dietzel","year":"2018","journal-title":"Europace"},{"key":"2026080913422452300_euaf019-B89","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1007\/s11606-021-06954-8","article-title":"Atrial fibrillation is associated with cognitive impairment, all-cause dementia, vascular dementia, and Alzheimer's disease: a systematic review and meta-analysis","volume":"36","author":"Papanastasiou","year":"2021","journal-title":"J Gen Intern Med"},{"key":"2026080913422452300_euaf019-B90","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1177\/0003319720910669","article-title":"Atrial fibrillation and cognitive impairment: an associated burden or burden by association?","volume":"71","author":"Manolis","year":"2020","journal-title":"Angiology"},{"key":"2026080913422452300_euaf019-B91","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1161\/CIRCULATIONAHA.121.056320","article-title":"MRI-detected brain lesions and cognitive function in atrial fibrillation patients undergoing left atrial catheter ablation in the randomized AXAFA-AFNET 5 trial","volume":"145","author":"Haeusler","year":"2022","journal-title":"Circulation"},{"key":"2026080913422452300_euaf019-B92","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ijcard.2017.05.102","article-title":"Incidence of MRI-detected brain lesions and neurocognitive function after electrical cardioversion in anticoagulated patients with persistent atrial fibrillation","volume":"243","author":"Bellmann","year":"2017","journal-title":"Int J Cardiol"},{"key":"2026080913422452300_euaf019-B93","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.hrthm.2017.11.015","article-title":"Left atrial appendage angiography is associated with the incidence and number of magnetic resonance imaging-detected brain lesions after percutaneous catheter-based left atrial appendage closure","volume":"15","author":"Rillig","year":"2018","journal-title":"Heart Rhythm"},{"key":"2026080913422452300_euaf019-B94","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/joa3.12050","article-title":"European Heart Rhythm Association (EHRA)\/Heart Rhythm Society (HRS)\/Asia Pacific Heart Rhythm Society (APHRS)\/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?","volume":"34","author":"Dagres","year":"2018","journal-title":"J Arrhythm"},{"key":"2026080913422452300_euaf019-B95","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jocn.2019.12.030","article-title":"Impact of atrial fibrillation burden on cognitive function after left atrial ablation\u2014results of the MACPAF study","volume":"73","author":"Herm","year":"2020","journal-title":"J Clin Neurosci"},{"key":"2026080913422452300_euaf019-B96","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijcard.2023.01.007","article-title":"Association between atrial fibrillation burden and cognitive function in patients with atrial fibrillation","volume":"377","author":"Tang","year":"2023","journal-title":"Int J Cardiol"},{"key":"2026080913422452300_euaf019-B97","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ahj.2021.08.006","article-title":"Atrial fibrillation burden and cognitive decline in elderly patients undergoing continuous monitoring","volume":"242","author":"Bonnesen","year":"2021","journal-title":"Am Heart J"},{"key":"2026080913422452300_euaf019-B98","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/euac062","article-title":"Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET\/EHRA consensus conference","volume":"25","author":"Schnabel","year":"2023","journal-title":"Europace"},{"key":"2026080913422452300_euaf019-B99","first-page":"S8","article-title":"A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation","volume":"86","author":"Krittayaphong","year":"2003","journal-title":"J Med Assoc Thai"},{"key":"2026080913422452300_euaf019-B100","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1001\/jama.293.21.2634","article-title":"Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial","volume":"293","author":"Wazni","year":"2005","journal-title":"JAMA"},{"key":"2026080913422452300_euaf019-B101","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1056\/NEJMoa1113566","article-title":"Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation","volume":"367","author":"Cosedis Nielsen","year":"2012","journal-title":"N Engl J Med"},{"key":"2026080913422452300_euaf019-B102","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/eurheartj\/ehi583","article-title":"Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (catheter ablation for the cure of atrial fibrillation study)","volume":"27","author":"Stabile","year":"2006","journal-title":"Eur Heart J"},{"key":"2026080913422452300_euaf019-B103","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa050955","article-title":"Circumferential pulmonary-vein ablation for chronic atrial fibrillation","volume":"354","author":"Oral","year":"2006","journal-title":"N Engl J Med"},{"key":"2026080913422452300_euaf019-B104","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1016\/j.jacc.2006.08.037","article-title":"A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF study","volume":"48","author":"Pappone","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026080913422452300_euaf019-B105","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1161\/CIRCULATIONAHA.108.772582","article-title":"Catheter ablation versus antiarrhythmic drugs for atrial fibrillation, the A4 study","volume":"118","author":"Ja\u00efs","year":"2008","journal-title":"Circulation"},{"key":"2026080913422452300_euaf019-B106","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1540-8167.2008.01275.x","article-title":"Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy","volume":"20","author":"Forleo","year":"2009","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026080913422452300_euaf019-B107","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/jama.2009.2029","article-title":"Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial","volume":"303","author":"Wilber","year":"2010","journal-title":"JAMA"},{"key":"2026080913422452300_euaf019-B108","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.jacc.2012.11.064","article-title":"Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial","volume":"61","author":"Packer","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080913422452300_euaf019-B109","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/eurheartj\/eht457","article-title":"Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study)","volume":"35","author":"Mont","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080913422452300_euaf019-B110","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jama.2014.467","article-title":"Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (raaft-2): a randomized trial","volume":"311","author":"Morillo","year":"2014","journal-title":"JAMA"},{"key":"2026080913422452300_euaf019-B111","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2029554","article-title":"Cryoballoon ablation as initial therapy for atrial fibrillation","volume":"384","author":"Wazni","year":"2021","journal-title":"N Engl J Med"},{"key":"2026080913422452300_euaf019-B112","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/europace\/euab029","article-title":"Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation","volume":"23","author":"Kuniss","year":"2021","journal-title":"Europace"},{"key":"2026080913422452300_euaf019-B113","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/europace\/euaa298","article-title":"Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST)","volume":"23","author":"Kuck","year":"2021","journal-title":"Europace"},{"key":"2026080913422452300_euaf019-B114","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2019.0693","article-title":"Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial","volume":"321","author":"Packer","year":"2019","journal-title":"JAMA"},{"key":"2026080913422452300_euaf019-B115","first-page":"100791","article-title":"Atrial fibrillation burden, episode duration and frequency in relation to quality of life in patients with implantable cardiac monitor","volume":"34","author":"Jansson","year":"2021","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2026080913422452300_euaf019-B116","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/pace.12772","article-title":"The impact of duration of atrial fibrillation recurrences on measures of health-related quality of life and symptoms","volume":"39","author":"Kochh\u00e4user","year":"2016","journal-title":"Pacing Clin Electrophysiol"},{"key":"2026080913422452300_euaf019-B117","first-page":"1211","article-title":"Relationship of quality of life with procedural success of atrial fibrillation (AF) ablation and postablation AF burden: substudy of the STAR AF randomized trial","volume":"29","author":"Mantovan","year":"2013","journal-title":"Can J Cardiol"},{"key":"2026080913422452300_euaf019-B118","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/eurheartj\/ehac692","article-title":"Healthcare utilization and quality of life for atrial fibrillation burden: the CIRCA-DOSE study","volume":"44","author":"Andrade","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080913422452300_euaf019-B119","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1016\/j.hrthm.2017.05.012","article-title":"2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation","volume":"14","author":"Calkins","year":"2017","journal-title":"Heart Rhythm"},{"key":"2026080913422452300_euaf019-B120","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1161\/CIRCULATIONAHA.119.042622","article-title":"Cryoballoon or radiofrequency ablation for atrial fibrillation assessed by continuous monitoring","volume":"140","author":"Andrade","year":"2019","journal-title":"Circulation"},{"key":"2026080913422452300_euaf019-B121","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/europace\/euz216","article-title":"Impact of monitoring on detection of arrhythmia recurrences in the ESC-EHRA EORP atrial fibrillation ablation long-term registry","volume":"21","author":"Balabanski","year":"2019","journal-title":"Europace"},{"key":"2026080913422452300_euaf019-B122","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.hrthm.2019.11.004","article-title":"Long-term impact of catheter ablation on arrhythmia burden in low-risk patients with paroxysmal atrial fibrillation: the CLOSE to CURE study","volume":"17","author":"Duytschaever","year":"2020","journal-title":"Heart Rhythm"},{"key":"2026080913422452300_euaf019-B123","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1111\/jce.14781","article-title":"Atrial fibrillation ablation success defined by duration of recurrence on cardiac implantable electronic devices","volume":"31","author":"Lohrmann","year":"2020","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026080913422452300_euaf019-B124","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.120.050991","article-title":"Ablation versus drug therapy for atrial fibrillation in heart failure results from the CABANA trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"2026080913422452300_euaf019-B125","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/CIRCULATIONAHA.121.056323","article-title":"Early rhythm control therapy in patients with atrial fibrillation and heart failure","volume":"144","author":"Rillig","year":"2021","journal-title":"Circulation"},{"key":"2026080913422452300_euaf019-B126","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2212540","article-title":"Progression of atrial fibrillation after cryoablation or drug therapy","volume":"388","author":"Andrade","year":"2023","journal-title":"N Engl J Med"},{"key":"2026080913422452300_euaf019-B127","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1161\/CIRCULATIONAHA.124.069757","article-title":"Association of atrial fibrillation burden and mortality among patients with cardiac implantable electronic devices","volume":"150","author":"Peigh","year":"2024","journal-title":"Circulation"},{"key":"2026080913422452300_euaf019-B128","doi-asserted-by":"crossref","first-page":"euae070","DOI":"10.1093\/europace\/euae070","article-title":"Longer and better lives for patients with atrial fibrillation: the 9th AFNET\/EHRA consensus conference","volume":"26","author":"Linz","year":"2024","journal-title":"Europace"}],"container-title":["Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/27\/3\/euaf019\/62387004\/euaf019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/27\/3\/euaf019\/62387004\/euaf019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T17:42:44Z","timestamp":1786297364000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/doi\/10.1093\/europace\/euaf019\/8071736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":128,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euaf019","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,3]]},"article-number":"euaf019"}}